As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster.
|Telephone:||+44 (0)1223 696 000|
|Address:||330 Cambridge Science Park, Cambridge|
|Membership type:||Founder Member|
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the Company’s products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam’s ten offices are located in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com
Abcam, a global leader in the supply of life science research tools, is pleased to announce that it has entered into a definitive licence agreement with Roche.
23 January 2018Read in full
Abcam plc, a global leader in the supply of life science research tools, announces that Alan Hirzel, Chief Executive Officer, will present at the 36th Annual JP Morgan Healthcare Conference in San Francisco, California, tomorrow (Wednesday, January 10, 2018), at 16:30 Pacific Standard Time.
9 January 2018Read in full
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces an unaudited trading update ahead of its results for the six months ended 31 December 2017.(1)
5 January 2018Read in full
Abcam plc, a global leader in the supply of life science research tools announces that its Chairman, Murray Hennessy, has informed the Board that he has accepted a CEO role and will therefore relinquish his Non-Executive Chairman position and step down from the Board following the AGM in November 2017.
12 October 2017Read in full
Abcam plc, a global leader in the supply of life science tools, is pleased to announce its preliminary results for the year ended 30 June 2017*.
11 September 2017Read in full
Joint developers of Cambridge Biomedical Campus (CBC), Liberty Property Trust and Countryside Properties have held a ground breaking ceremony with Abcam Plc to commemorate the start of construction of Abcam’s new 100,000 sq ft global headquarters.
7 June 2017Read in full
Abcam plc, a global leader in the supply of life science research tools, is delighted to announce that further to its acquisition of AxioMx, Inc. in November 2015 the final performance-related milestones have been successfully achieved.
18 May 2017Read in full
Abcam plc, a global leader in the supply of life science research tools, announces that it has committed to the lease of a new facility for its global headquarters at the expanding Biomedical Campus in Cambridge, UK, subject to the grant of full planning approval.
24 October 2016Read in full